BioMarin Pharmaceuticals
BMRN
280 hedge funds and large institutions have $7.98B invested in BioMarin Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 280 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
16% less call options, than puts
Call options by funds: $36.2M | Put options by funds: $43M
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PTC
276
Private Trust Company
Cleveland,
Ohio
| $3K | +$3.12K | +50 | New |
|
|
RFA
277
Reilly Financial Advisors
La Mesa,
California
| $3K | +$3.12K | +50 | New |
|
278
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $2K | +$1.99K | +32 | New |
|
279
Loomis, Sayles & Company
Boston,
Massachusetts
| $1.65K | +$1.84M | +29,529 | New |
|
|
PG
280
PEAK6 Group
Chicago,
Illinois
| $139 | +$156K | +2,500 | New |
|
BMRN Hedge Fund Activity: Q2 2013 in Review
280 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2013, worth a combined $7.98B.
Buyers outnumbered sellers: 280 funds opened new BMRN positions and 0 closed out — a net gain of 280 holders — while 0 added to existing stakes and 0 trimmed.
- 280 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $7.98B of BioMarin Pharmaceuticals stock for Q2 2013.
- 280 funds opened new BioMarin Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +280 holders.
Based on aggregated 13F filings for Q2 2013.